Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
REVENUES:    
Product revenue, net $ 6,878 $ 2,429
COSTS AND EXPENSES:    
Cost of sales 1,578 943
Research and development 18,213 7,436
Selling general and administrative 28,624 10,104
Total operating expenses 48,415 18,483
Operating loss (41,537) (16,054)
Grant income 0 923
Loss on Extinguishment of Debt 0 (2,092)
Interest income 1,346 394
Other expense, net (3)
Net loss available to common stockholders $ (40,194) $ (16,829)
Net loss to common stockholders per common share, basic $ (2.93) $ (2.84)
Net loss to common stockholders per common share, diluted $ (2.93) $ (2.84)
Weighted average common shares outstanding, basic 13,707,104 5,927,231
Weighted average common shares outstanding, diluted 13,707,104 5,927,231